Company Research Report: 4D Molecular Therapeutics

Company Overview

• Name: 4D Molecular Therapeutics

• Mission: To boldly innovate and unlock the full potential of genetic medicines for large market diseases by harnessing directed evolution to invent customized and enhanced vectors for transformative patient products.

• Founded: No information is available

• Founders: No information is available

• Key People:

• David Kirn, MD - Chief Executive Officer, Co-Founder

• Fred Kamal, PhD - President, Chief Operating Officer

• Theresa Janke - Chief of Staff, Co-Founder

• Robert Kim, MD - Chief Medical Officer

• Dhaval Desai, PharmD - Chief Development Officer

• Carlos Quezada-Ruiz, MD, FASRS - Senior Vice President, Therapeutic Area Head, Ophthalmology

• An Song, PhD - Chief Research & Translational Development Officer

• Noriyuki Kasahara, MD, PhD - Chief Scientific Officer

• Uneek Mehra - Chief Financial & Business Officer

• Chris Simms - Chief Commercial Officer

• Scott Bizily, JD, PhD - Chief Legal Officer

• Headquartered: 5858 Horton St. Suite 455, Emeryville, CA 94608

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Inventing and developing genetic medicines with proprietary customized vectors optimized for specific diseases in fields such as ophthalmology, pulmonology, and cardiology.

Products

R100

• Product Type: Vector for retinal diseases

• Key Features:

• Designed for low-dose intravitreal delivery to the retina

• Primate-evolved for full retinal coverage at low doses without requiring sub-retinal surgery

A101

• Product Type: Vector for lung delivery

• Key Features:

• Efficient aerosol delivery to lung airways

• Penetrates mucus barriers for effective transduction

• Resistant to pre-existing antibodies

C102

• Product Type: Vector for cardiac delivery

• Key Features:

• Low-dose intravenous delivery to muscle cells

• Specifically targets human cardiomyocytes for efficient transduction

Recent Developments

Clinical Trials

• 4D-150: Currently in Phase 2 clinical trials for treating wet age-related macular degeneration (AMD). The treatment has shown significant promise in reducing the need for standard injections by 89% and achieving injection-free status for 70% of certain patients for extended periods.

Product Pipeline Progress

• Expansion of the product pipeline to include treatments for diabetic macular edema (DME), geographic atrophy, choroideremia, and X-linked retinitis pigmentosa.

• Expected to progress clinical trials and release important datasets for wet AMD, DME, and cystic fibrosis throughout 2024.

Partnerships

• A licensing agreement with Astellas Pharma for the use of viral vectors for treating a rare monogenic ophthalmic disease, potentially worth up to $962 million.

Regulatory Progress

• Phase 2 trials for multiple products have been granted RMAT and PRIME designations by FDA and EMA, expediting their development and approval processes.

Summary

4D Molecular Therapeutics stands at the forefront of genetic medicine, focusing on the development of transformative therapies through innovative vector technology. With a robust pipeline spanning multiple large-market diseases and strategic partnerships that enhance its development reach, 4DMT is poised to become a leader in the biotechnology industry, offering significant advancements in the treatment of conditions that are currently unmet by existing therapies.